Abstract
Purpose
High GH and IGF I levels increase tubular phosphate reabsorption in patients with acromegaly. We aimed to investigate the utility of serum phosphorus levels as an indicator for predicting chance of remission in acromegaly patients.
Design
Fifty-one patients (n: 51; F: 24, M: 27) with diagnosis of acromegaly were included in the study. Plasma IGF-1, Phosphorus (P) and nadir GH levels on oral glucose tolerance test (OGTT) at the time of diagnosis were analysed retrospectively. Patients were classified into two groups according to their plasma P levels; P ≤ 4.5 mg/dl (Group-1, n: 23, 45.1%), P > 4.5 mg/dl (Group-2, n: 28, 54.9%). Two groups were compared according to remission status; remission (n: 27) and non-remission (n: 24). Remission was defined with absence of clinical symptoms, normal plasma IGF-1 (adjusted for age and gender) and GH levels (<1 mcg/dl) at least 3 months after initial treatment.
Results
Serum P levels decreased significantly after treatment in both groups (p < 0.001). There was a significant correlation between baseline phosphorus levels and remission rates, nadir GH in OGTT, pituitary adenoma size and Ki-67 scores (p = 0.001, r: −0.51; p = 0.01, r: 0.44; p = 0.001, r: 0.52; p = 0.02, r: 0.71, respectively). Mean baseline P levels were significantly higher in patients with non-remission (4.8 vs 4.2, P < 0.001). Logistic regression analysis did not reveal an independent effect on remission with any of these risk factors.
Conclusion
High serum P levels may be an indicator for a low likelihood of onset of remission in acromegaly patients. Further studies with wider spectrum are needed to make specific suggestions.
Similar content being viewed by others
References
Melmed SS (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573
Chanson P, Salenave S (2008) Acromegaly. Orphanet J Rare Dis 3:17
Takamoto S, Tsuchiya H, Onishi T (1985) Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab 61:7–11
Menaa C, Vrtovsnik F, Friedlander G (1995) Insulin-like growth factor I, a unique calcium-dependent stimulator of 1.25-dihydroxyvitamin D3 production. Studies in cultured mouse kidney cells. J Biol Chem 270:25461–25467
Corvilain J, Abramow M, Bergans A (1962) Some effects of human growth hormone on renal hemodynamics and on tubular phosphate transport in man. J Clin Invest 41:1230–1235
Quigley R, Baum M (1991) Effects of growth hormone and insulin like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 88:368–374
Mori R, Inoshita N, Takahashi-Fujigasaki J (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution, ISRN. Endocrinol 2013:723432. doi:10.1155/2013/723432
Sievers C, Baur DM, Schwanke A (2015) Prediction of therapy response in acromegalic patients. Pitutary 18:916–923
Resmini E, Minuto F, Colao A et al (2009) Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 46:85–95
Lederer E (2014) Regulation of serum phosphate. J Physiol 592(18):3985–3995
Droste M, Domberg J, Buchfelderet al M (2014) Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol 17:159–168
Lund B, Eskildsen PC, Lund B (1981) Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh) 96:444–450
Camanni F, Massara F, Losana O, Molinatti GM (1968) Increased renal tubular reabsorption of phosphorus in acromegaly. J Clin Endocrinol Metab 28(7):999–1005
Tonelli M, Sacks F, Pfeffer M (2005) Cholesterol and recurrent events trial investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627–2633
Foley RN (2009) Phosphate levels and cardiovascular disease in the general population Clin Am Soc Nephrol 4:1136–1139.
Van der Meer IM, Middelkoop BJC, Boeke AJP, Lips P (2011) Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos Int 22(4):1009–1021
Shimada T, Kakitani M, Yamazaki Y (2004) Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568
Ito N, Fukumoto S, Taguchi M (2007) Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr J 54:481–484
Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820–3828
Sze L, Bernays RL, Zwimpfer C (2012) Excessively high soluble Klotho in patients with acromegaly. J Intern Med 272:93–97
Jawiarczyk-Przybyłowska A, Halupczok-Zyla J, Bolanowski M (2016) Soluble α-Klotho—a new marker of acromegaly? Endokrynol Pol 67:390–396
Parkinson C, Ryder WD, Trainer PJ et al (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender specific. J Clin Endocrinol Metab 86:5240–5244
Bianda T, Hussain MA, Glatz Y (1997) Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D production in healthy man. J Intern Med 241:143–150
Kamenický P, Blanchard A, Gauci C (2012) Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria. J Clin Endocrinol Metab 97:2124–2133
Kurosu H, Ogawa Y, Miyosh M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123
Bhayana S, Booth GL, Asaet al SL (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290–6295
Turner HE, Wass JA et al (1999) Are markers of proliferation valuable in the histological assessment of pituitary tumours. Pituitary 1:147–151
Thapar K, Kovacset al K (1996) BW Scheithauer. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106
DeLellis RA, Lloyd RV, Heitz PU (2004) World Health Organization classification of tumors: tumors of endocrine organs. IARC Press, Lyon, France
Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ (2009) Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 160:543–548
Acknowledgements
The authors are grateful to Professor Nese Colak Ozbey from Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Division of Endocrinology and Metabolism Disorders for review of this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the Ethics Committee of Istanbul University Istanbul Medical Faculty, and all procedures were performed in accordance with the Declaration of Helsinki.
Informed consent
Informed consent was obtained from all individuals included in the study.
Rights and permissions
About this article
Cite this article
Yalin, G.Y., Tanrikulu, S., Gul, N. et al. Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients. J Endocrinol Invest 40, 867–874 (2017). https://doi.org/10.1007/s40618-017-0657-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-017-0657-3